{
    "Trade/Device Name(s)": [
        "Urea Nitrogen2"
    ],
    "Submitter Information": "Abbott Ireland Diagnostics Division",
    "510(k) Number": "K203771",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981918"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CDQ"
    ],
    "Summary Letter Date": "February 28, 2022",
    "Summary Letter Received Date": "March 2, 2022",
    "Submission Date": "May 24, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1770"
    ],
    "Regulation Name(s)": [
        "Urea nitrogen test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Urea nitrogen"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Lithium heparin tube",
        "Lithium heparin separator tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c System"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay",
        "Urease-based kinetic assay"
    ],
    "Methodologies": [
        "Enzymatic quantitation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Urea Nitrogen2 enzymatic assay for quantitation of urea nitrogen in human serum, plasma, and urine on the ARCHITECT c System",
    "Indications for Use Summary": "For quantitation of urea nitrogen in human serum, plasma, or urine as an aid in the diagnosis and treatment of certain renal and metabolic diseases",
    "fda_folder": "Clinical Chemistry"
}